Alcolase Raises €1.5M for Alcohol Intolerance Enzyme Tech

Danish biotechnology firm Alcolase has successfully closed a €1.5 million funding round, drawing investment from prominent venture capital firms including Ada Ventures, Delphinus Venture Capital, and Antler, alongside contributions from Manigoff Invest and a cohort of business angels. This capital infusion is earmarked to advance the development of a novel enzyme-based solution designed to mitigate the physiological effects of alcohol intolerance.

The core innovation from Alcolase centers on a proprietary encapsulation technology that shields enzymes from stomach acidity, enabling them to function effectively within the stomach. This approach targets the significant global population, particularly in East Asia, affected by ALDH2 deficiency. This genetic condition impairs the body's ability to metabolize alcohol, leading to uncomfortable symptoms like flushing and nausea, and increasing long-term health risks associated with alcohol consumption. The company's mission is to offer individuals with this deficiency a greater degree of social and personal choice in environments where alcohol consumption is prevalent.

The market for solutions addressing alcohol intolerance is substantial, with estimates suggesting hundreds of millions worldwide are impacted by ALDH2 deficiency. Traditional approaches often focus on abstinence, which can lead to social and professional exclusion in cultures where drinking is integral to business and social interactions. Alcolase aims to provide a scientifically-backed alternative, allowing individuals to navigate social events without the adverse physical reactions, thereby fostering greater inclusion. This aligns with a growing trend in healthtech towards personalized solutions for specific genetic predispositions.

Mikkel Precht, CEO and Co-founder of Alcolase, emphasized the social dimension of their work: "Our motivation stems from the realization that for many, alcohol intolerance isn't a lifestyle choice but a genetic reality that can lead to exclusion from crucial social and professional gatherings. We are leveraging biotechnology to address a tangible everyday problem, offering a healthier option where one is currently limited." The company's strategic vision includes initial market entry in Singapore, followed by South Korea, regions with a high prevalence of ALDH2 deficiency.

To facilitate its expansion and therapeutic development, Alcolase has established a subsidiary in the United Kingdom, with Ada Ventures playing a key role in supporting this move into the UK's robust life sciences sector. Check Warner, Co-founding Partner at Ada Ventures, commented on the investment, stating, "Alcolase embodies our investment thesis: a science-driven team addressing a widespread issue. We are enthusiastic about backing their UK expansion and the potential of their drug delivery platform." Alasdair Thong, Venture Partner at Ada Ventures, will join the company's board.

The newly secured funding will propel Alcolase through several critical developmental stages. Key objectives include the execution of in vivo studies, further refinement of their core technology, bolstering their intellectual property portfolio, and initiating commercial discussions and partnerships in target markets. This strategic advancement positions Alcolase to make significant strides in offering a novel therapeutic option for a condition affecting a vast global demographic.